Lifecore Biomedical Ownership
| LFCR Stock | 6.09 0.15 2.53% |
Shares in Circulation | First Issued 1995-12-31 | Previous Quarter 30.9 M | Current Value 34.4 M | Avarage Shares Outstanding 24.2 M | Quarterly Volatility 5.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Lifecore |
Lifecore Stock Ownership Analysis
About 76.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.56. Lifecore Biomedical had not issued any dividends in recent years. To find out more about Lifecore Biomedical contact James Hall at (952) 368-4300 or learn more at https://www.lifecore.com.Besides selling stocks to institutional investors, Lifecore Biomedical also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Lifecore Biomedical's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Lifecore Biomedical's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Lifecore Biomedical Quarterly Liabilities And Stockholders Equity |
|
About 5.0% of Lifecore Biomedical are currently held by insiders. Unlike Lifecore Biomedical's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Lifecore Biomedical's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Lifecore Biomedical's insider trades
Lifecore Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Lifecore Biomedical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lifecore Biomedical backward and forwards among themselves. Lifecore Biomedical's institutional investor refers to the entity that pools money to purchase Lifecore Biomedical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Deutsche Bank Ag | 2024-09-30 | 315.7 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 200.7 K | Northern Trust Corp | 2024-09-30 | 193.5 K | Boothbay Fund Management, Llc | 2024-09-30 | 187.1 K | Tocqueville Asset Management L.p. | 2024-12-31 | 151.7 K | B. Riley Asset Management, Llc | 2024-09-30 | 143.5 K | Quinn Opportunity Partners Llc | 2024-09-30 | 127.9 K | Qube Research & Technologies | 2024-09-30 | 94.4 K | Gamco Investors, Inc. Et Al | 2024-12-31 | 86 K | Wynnefield Capital Inc | 2024-12-31 | 4.7 M | Legion Partners Asset Management, Llc | 2024-09-30 | 3 M |
Lifecore Biomedical Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lifecore Biomedical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lifecore Biomedical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lifecore Biomedical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
John Morberg over a month ago Disposition of 17500 shares by John Morberg of Lifecore Biomedical subject to Rule 16b-3 | ||
Paul Josephs over a month ago Acquisition by Paul Josephs of 17000 shares of Lifecore Biomedical at 5.74 subject to Rule 16b-3 | ||
Lake Ryan David over two months ago Disposition of 5653 shares by Lake Ryan David of Lifecore Biomedical at 7.15 subject to Rule 16b-3 | ||
Kiper Christopher S over six months ago Discretionary transaction by Kiper Christopher S of 105110 shares of Lifecore Biomedical subject to Rule 16b-3 | ||
Houde Lovas Katrina over six months ago Acquisition by Houde Lovas Katrina of 9474 shares of Lifecore Biomedical subject to Rule 16b-3 | ||
Wynnefield Partners Small Cap Value Lp I over a year ago Purchase by Wynnefield Partners Small Cap Value Lp I of 282486 shares of Lifecore Biomedical | ||
Wynnefield Partners Small Cap Value Lp I over a year ago Purchase by Wynnefield Partners Small Cap Value Lp I of 2508 shares of Lifecore Biomedical |
Lifecore Biomedical Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
| 21st of January 2025 Other Reports | ViewVerify | |
8K | 17th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 8th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Additional Tools for Lifecore Stock Analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.